Evidence map›Paper›PMID 32937143›Full record

ArticleAmerican journal of human genetics2020

De Novo and Inherited Variants in GBF1 are Associated with Axonal Neuropathy Caused by Golgi Fragmentation.

Natalia Mendoza-Ferreira, Mert Karakaya, Nur Cengiz, Danique Beijer, Karlla W Brigatti, Claudia Gonzaga-Jauregui, Nico Fuhrmann, Irmgard Hölker, Maximilian P Thelen, Sebastian Zetzsche and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A NovelGenes · 2024
    Article
  5. Review
  6. STING trafficking as a new dimension of immune signaling.The Journal of experimental medicine · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. STING Operation at the ER/Golgi Interface.Frontiers in immunology · 2021
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 3 countries.

Natalia Mendoza-FerreiraInstitute of Human Genetics, Center for Molecular Medicine Cologne, Center for Rare Diseases Cologne, and Institute for Genetics, University of Cologne, 50931 Cologne, Germany.
Mert KarakayaInstitute of Human Genetics, Center for Molecular Medicine Cologne, Center for Rare Diseases Cologne, and Institute for Genetics, University of Cologne, 50931 Cologne, Germany.
Nur CengizInstitute of Human Genetics, Center for Molecular Medicine Cologne, Center for Rare Diseases Cologne, and Institute for Genetics, University of Cologne, 50931 Cologne, Germany.
Danique BeijerTranslational Neurosciences, Faculty of Medicine, University of Antwerp, B-2610 Wilrijk, Belgium; Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, B-2610 Wilrijk, Belgium.
Karlla W BrigattiClinic for Special Children, Strasburg, PA 17579, USA.
Claudia Gonzaga-JaureguiRegeneron Genetics Center, Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Nico FuhrmannInstitute of Human Genetics, Center for Molecular Medicine Cologne, Center for Rare Diseases Cologne, and Institute for Genetics, University of Cologne, 50931 Cologne, Germany.
Irmgard HölkerInstitute of Human Genetics, Center for Molecular Medicine Cologne, Center for Rare Diseases Cologne, and Institute for Genetics, University of Cologne, 50931 Cologne, Germany.
Maximilian P ThelenInstitute of Human Genetics, Center for Molecular Medicine Cologne, Center for Rare Diseases Cologne, and Institute for Genetics, University of Cologne, 50931 Cologne, Germany.
Sebastian ZetzscheInstitute of Human Genetics, Center for Molecular Medicine Cologne, Center for Rare Diseases Cologne, and Institute for Genetics, University of Cologne, 50931 Cologne, Germany.
Roman RomboInstitute of Human Genetics, Center for Molecular Medicine Cologne, Center for Rare Diseases Cologne, and Institute for Genetics, University of Cologne, 50931 Cologne, Germany.
Erik G PuffenbergerClinic for Special Children, Strasburg, PA 17579, USA.
Peter De JongheTranslational Neurosciences, Faculty of Medicine, University of Antwerp, B-2610 Wilrijk, Belgium; Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, B-2610 Wilrijk, Belgium; Neuromuscular Reference Centre, Department of Neurology, Antwerpen University Hospital, B-2650 Edegem, Belgium.
Tine DeconinckTranslational Neurosciences, Faculty of Medicine, University of Antwerp, B-2610 Wilrijk, Belgium; Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, B-2610 Wilrijk, Belgium.
Stephan ZuchnerDr. John T. Macdonald Foundation Department of Human Genetics and Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, 33136 FL, USA.
Kevin A StraussRegeneron Genetics Center, Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Vincent CarsonClinic for Special Children, Strasburg, PA 17579, USA.
Bertold SchrankDKD Helios Klinik, Department of Neurology, 65191 Wiesbaden, Germany.
Gilbert WunderlichDepartment of Neurology and Center for Rare Diseases, University Hospital Cologne, 50931 Cologne, Germany.
Jonathan BaetsTranslational Neurosciences, Faculty of Medicine, University of Antwerp, B-2610 Wilrijk, Belgium; Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, B-2610 Wilrijk, Belgium; Neuromuscular Reference Centre, Department of Neurology, Antwerpen University Hospital, B-2650 Edegem, Belgium.
Brunhilde WirthInstitute of Human Genetics, Center for Molecular Medicine Cologne, Center for Rare Diseases Cologne, and Institute for Genetics, University of Cologne, 50931 Cologne, Germany. Electronic address: brunhilde.wirth@uk-koeln.de.
University of Cologne · DEUniversity of Antwerp · BEClinic for Special Children · USRegeneron (United States) · USHelios Kliniken · DEUniversity Hospital Cologne · DEUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Distal hereditary motor neuropathies (HMNs) and axonal Charcot-Marie-Tooth neuropathy (CMT2) are clinically and genetically heterogeneous diseases characterized primarily by motor neuron degeneration and distal weakness. The genetic cause for about half of the individuals affected by HMN/CMT2 remains unknown. Here, we report the identification of pathogenic variants in GBF1 (Golgi brefeldin A-resistant guanine nucleotide exchange factor 1) in four unrelated families with individuals affected by sporadic or dominant HMN/CMT2. Genomic sequencing analyses in seven affected individuals uncovered four distinct heterozygous GBF1 variants, two of which occurred de novo. Other known HMN/CMT2-implicated genes were excluded. Affected individuals show HMN/CMT2 with slowly progressive distal muscle weakness and musculoskeletal deformities. Electrophysiological studies confirmed axonal damage with chronic neurogenic changes. Three individuals had additional distal sensory loss. GBF1 encodes a guanine-nucleotide exchange factor that facilitates the activation of members of the ARF (ADP-ribosylation factor) family of small GTPases. GBF1 is mainly involved in the formation of coatomer protein complex (COPI) vesicles, maintenance and function of the Golgi apparatus, and mitochondria migration and positioning. We demonstrate that GBF1 is present in mouse spinal cord and muscle tissues and is particularly abundant in neuropathologically relevant sites, such as the motor neuron and the growth cone. Consistent with the described role of GBF1 in Golgi function and maintenance, we observed marked increase in Golgi fragmentation in primary fibroblasts derived from all affected individuals in this study. Our results not only reinforce the existing link between Golgi fragmentation and neurodegeneration but also demonstrate that pathogenic variants in GBF1 are associated with HMN/CMT2.

Indexed as

AdultAgedAged, 80 and overAmino Acid SequenceAnimalsAxonsCharcot-Marie-Tooth DiseaseCOP-Coated VesiclesFemaleFibroblastsGene ExpressionGolgi ApparatusGuanine Nucleotide Exchange FactorsHeterozygoteHumansMaleGBF1 protein, humanGuanine Nucleotide Exchange FactorsCharcot-Marie-Tooth neuropathyde novodominant variantsexomeGBF1genomeGolgi fragmentationmotor neuropathyneuromuscular disordernext-generation sequencing

Identifiers

PMID32937143
PMCPMC7491385
OpenAlexW3086820607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.